139 related articles for article (PubMed ID: 21266894)
21. Closing Remarks.
Reed E
Oncologist; 1996; 1(4):276-277. PubMed ID: 10388002
[TBL] [Abstract][Full Text] [Related]
22. Alternative strategies in drug development: clinical pharmacological aspects.
Kuhlmann J
Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
[TBL] [Abstract][Full Text] [Related]
23. [Psychopharmacotherapy in the 20th century].
Siepmann M; Kirch W
Wien Med Wochenschr; 2001; 151(15-17):397-402. PubMed ID: 11603211
[TBL] [Abstract][Full Text] [Related]
24. Comparative psychology and the grand challenge of drug discovery in psychiatry and neurodegeneration.
Brunner D; Balcı F; Ludvig EA
Behav Processes; 2012 Feb; 89(2):187-95. PubMed ID: 22155361
[TBL] [Abstract][Full Text] [Related]
25. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
26. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
Workman P
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
[TBL] [Abstract][Full Text] [Related]
27. Animal models of depression: challenges from a drug development perspective.
Rupniak NM
Behav Pharmacol; 2003 Sep; 14(5-6):385-90. PubMed ID: 14501252
[TBL] [Abstract][Full Text] [Related]
28. An historical overview of drug discovery.
Pina AS; Hussain A; Roque AC
Methods Mol Biol; 2009; 572():3-12. PubMed ID: 20694682
[TBL] [Abstract][Full Text] [Related]
29. Mysteries of the brain. Why is mental illness so hard to treat?
Miller G
Science; 2012 Oct; 338(6103):32-3. PubMed ID: 23042865
[No Abstract] [Full Text] [Related]
30. CNS drug development: lessons from the development of ondansetron, aprepitant, ramelteon, varenicline, lorcaserin, and suvorexant. Part I.
Preskorn SH
J Psychiatr Pract; 2014 Nov; 20(6):460-5. PubMed ID: 25406050
[TBL] [Abstract][Full Text] [Related]
31. Beware the Medical-Industrial Complex.
Stevens CW; Glatstein E
Oncologist; 1996; 1(4):IV-V. PubMed ID: 10388005
[TBL] [Abstract][Full Text] [Related]
32. Apomorphine SL (Uprima): preclinical and clinical experiences learned from the first central nervous system-acting ED drug.
Giuliano F; Allard J
Int J Impot Res; 2002 Feb; 14 Suppl 1():S53-6. PubMed ID: 11850736
[TBL] [Abstract][Full Text] [Related]
33. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009.
Kaitin KI; DiMasi JA
Clin Pharmacol Ther; 2011 Feb; 89(2):183-8. PubMed ID: 21191382
[TBL] [Abstract][Full Text] [Related]
34. A perspective on risks that impede development of drugs to modify the course of Alzheimer's disease: can they be reduced?
Mohs RC
Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S85-7. PubMed ID: 18632007
[TBL] [Abstract][Full Text] [Related]
35. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
36. Safety and regulatory requirements and challenge for CNS drug development.
Gad SC
Neurobiol Dis; 2014 Jan; 61():39-46. PubMed ID: 24090873
[TBL] [Abstract][Full Text] [Related]
37. Family pediatrics: report of the Task Force on the Family.
Schor EL;
Pediatrics; 2003 Jun; 111(6 Pt 2):1541-71. PubMed ID: 12777595
[TBL] [Abstract][Full Text] [Related]
38. Progress in brain penetration evaluation in drug discovery and development.
Liu X; Chen C; Smith BJ
J Pharmacol Exp Ther; 2008 May; 325(2):349-56. PubMed ID: 18203948
[TBL] [Abstract][Full Text] [Related]
39. Representation and analysis of molecular networks involving diseases and drugs.
Kanehisa M
Genome Inform; 2009 Oct; 23(1):212-3. PubMed ID: 20180276
[TBL] [Abstract][Full Text] [Related]
40. The development of new analgesics over the past 50 years: a lack of real breakthrough drugs.
Kissin I
Anesth Analg; 2010 Mar; 110(3):780-9. PubMed ID: 20185657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
